Stay updated on Avelumab Program Rollover Study Clinical Trial
Sign up to get notified when there's something new on the Avelumab Program Rollover Study Clinical Trial page.

Latest updates to the Avelumab Program Rollover Study Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.4.2 was added. The previous government funding notice and Revision: v3.4.1 were removed.SummaryDifference0.2%

- Check21 days agoChange DetectedAdded a funding-status notice about government funding lapse and the NIH Clinical Center's status. Updated the page revision tag from v3.4.0 to v3.4.1.SummaryDifference0.2%

- Check28 days agoChange DetectedMinor UI and metadata updates were implemented: a glossary toggle was added and new Last Update fields (Last Update Submitted that Met QC Criteria, Last Update Posted) appeared, along with a revision label (Revision: v3.4.0). The core study content remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check42 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4. This is a minor version/documentation change that does not affect study data or how the page is used; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check63 days agoChange DetectedLocations section updated to include a full list of site states with revision v3.3.3. Individual per-state location blocks were removed.SummaryDifference1%

- Check78 days agoChange DetectedAdded EU Trial (CTIS) Number 2024-514274-46-00 and updated location details to 104 sites, including Vinnytsia, Ukraine (21029), with primary completion date 2027-02-19. Removed note that the study had 103 locations and the old 'Last Update Posted' timestamp.SummaryDifference0.3%

Stay in the know with updates to Avelumab Program Rollover Study Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Avelumab Program Rollover Study Clinical Trial page.